Showing 1,541 - 1,560 results of 1,895 for search '(((((( terms increase ) OR ( lies decrease ))) OR ( peer decrease ))) OR ( mean decrease ))*', query time: 0.10s Refine Results
  1. 1541
  2. 1542
  3. 1543
  4. 1544
  5. 1545
  6. 1546
  7. 1547
  8. 1548
  9. 1549
  10. 1550
  11. 1551
  12. 1552
  13. 1553
  14. 1554
  15. 1555
  16. 1556
  17. 1557
  18. 1558
  19. 1559

    Reply to Comments by Kakkar and Dahiya by Chahine, Elias B.

    Published 2014
    “…TO THE EDITOR: Chahine, Karaoui, and Mansour1 reviewed the efficacy and safety of bedaquiline in the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) and generally agree with the comments made by Kakkar and Dahiya.2 Bedaquiline was approved by the Food and Drug Administration based largely on results from phase 2 studies using sputum conversion as a surrogate marker for efficacy rather than long-term mortality data.2 Bedaquiline was shown to be associated with an unfavorable side effect profile, including an unexplained increased risk of mortality, QT prolongation, and elevated liver function tests.2 However, it is important to acknowledge that bedaquiline is the first novel drug to be approved for the treatment of TB in more than 4 decades and the communities devastated by MDR-TB are in desperate need for more options to manage their patients. …”
    Get full text
    Get full text
    Get full text
    Get full text
    article
  20. 1560